Specialty Pharma Journal Specialty, Precision & Technology
ANDOVER, Mass., Sept. 15, 2016 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the greater Boston biopharma hub. With 90 integrated scientists at a state-of-the-art research facility in Andover, …
Tag Archives: eisai
September, 2016
May, 2016
-
16 May
FDA Expands Approval of Eisai’s Lenvima in Kidney Cancer
WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an …
-
2 May
FDA Approves Oral Suspension Formulation of Eisai’s Fycompa
WOODCLIFF LAKE, N.J., May 2, 2016 /PRNewswire/ — Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in …
February, 2016
-
3 February
Morphotek and Mayo Clinic Partner to Study Diagnostic Assays in Triple-Negative Breast Cancer
EXTON, Pa., Feb. 3, 2016 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the Department of Immunology and Edith A. Perez, M.D. in the Department of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida in a …
January, 2016
-
19 January
Eisai’s Kidney Cancer Drug Receives Priority Review from the FDA
WOODCLIFF LAKE, N.J., Jan. 17, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for lenvatinib for the potential treatment of patients with unresectable advanced or metastatic renal cell carcinoma (RCC) in combination with …
December, 2015
-
7 December
Morphotek Announces Early-Stage Results from its Rheumatoid Arthritis Study
EXTON, Pa., Dec. 7, 2015 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending, placebo-controlled, Phase 1 trial evaluating the safety and tolerability of its investigational, anti-GM-CSF, monoclonal antibody, MORAb-022 in healthy subjects (n=26) and mild-to-moderate Rheumatoid Arthritis (RA) patients (n=25). In this …
November, 2015
-
9 November
Morphotek Enters License Agreement with Blaze Bioscience for Novel Oncology Imaging Technology
EXTON, Pa., Nov. 9, 2015 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company developing Tumor Paint technology. Under the agreement, Morphotek provides to Blaze an exclusive, worldwide, royalty-bearing …
March, 2015
-
5 March
Eisai and Merck Partner to Explore Novel Combination Regimens for Cancer
Japanese pharmaceutical firm Eisai has entered into a clinical trial collaboration to evaluate the combination of Merck’s anti-PD-1 drug with Eisai oncology compounds. The companies have teamed up to evaluate the safety, tolerability and efficacy of Merck’s Keytruda (pembrolizumab) in combination with Eisai’s Lenvima (lenvatinib) and Halaven (eribulin mesylate) in …
February, 2015
-
13 February
FDA Expands Approval of Eisai’s Banzel for Pediatric Patients Ages 1-4
Eisai Inc. announced that US health regulators expanded approval of Banzel (rufinamide) as an adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients. The company said that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Banzel for treatment of …
-
13 February
Eisai’s Thyroid Cancer Drug Receives Early FDA Approval
The US Food and Drug Administration (FDA) has granted an early approval to Eisai’s drug for the most common form of thyroid cancer. The agency announced that it has approved the Japanese drugmaker’s Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive …